PEMAZYRE 9 mg, comprimé — plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)
Medicine package · Base de données publique des médicaments (BDPM), ANSM, HAS et Assurance Maladie · France
-
CIP13
3400930223703 -
CIP7
3022370 -
CIS
61156252 -
Registration number
EU/1/21/1535
What the source publishes
- Holder
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Active ingredients
- PÉMIGATINIB
- Form
- comprimé
- Package
- plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)
- Routes
- orale
- Administrative status
- authorised
- Supply regime
- médicament nécessitant une surveillance particulière pendant le traitement ; prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE ; prescription hospitalière ; liste I ; prescription réservée aux médecins compétents en CANCEROLOGIE
- Marketing status
- Déclaration de commercialisation
- Authorised on
- 2021-03-26
- Prescription
- Prescription or restricted
Names this record is found by
- PEMAZYRE 9 mg, comprimé — plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)
- PEMAZYRE 9 mg, comprimé
- PÉMIGATINIB
Complete source data
{
"cis": "61156252",
"cip7": "3022370",
"form": "comprimé",
"name": "PEMAZYRE 9 mg, comprimé — plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)",
"cip13": "3400930223703",
"holder": "INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)",
"routes": [
"orale"
],
"holders": [
"INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)"
],
"currency": "EUR",
"marketed": true,
"bdmStatus": null,
"useDomain": "unknown",
"publicPrice": "6449.40",
"authorisedOn": "2021-03-26",
"compositions": [
{
"name": "PÉMIGATINIB",
"nature": "SA",
"strength": "9 mg",
"linkageNumber": "1",
"substanceCode": "48016",
"dosageReference": "un comprimé",
"pharmaceuticalElement": "comprimé"
}
],
"sourceStatus": "Présentation active",
"supplyRegime": "médicament nécessitant une surveillance particulière pendant le traitement ; prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE ; prescription hospitalière ; liste I ; prescription réservée aux médecins compétents en CANCEROLOGIE",
"dispensingFee": "1.02",
"medicinePrice": "6448.38",
"regionalRules": "not-collected",
"targetSpecies": [],
"specialityName": "PEMAZYRE 9 mg, comprimé",
"marketingStatus": "Déclaration de commercialisation",
"publicationDates": {
"CIS_bdpm": "2026-01-08",
"CIS_CIP_bdpm": "2026-11-19",
"CIS_CPD_bdpm": "2026-01-08",
"CIS_COMPO_bdpm": "2026-01-08"
},
"specialityListed": true,
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "fr.ansm.bdpm"
},
"collectiveApproval": "oui",
"packageDescription": "plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)",
"patientEligibility": "not-assessed",
"reimbursementRates": [
"100%"
],
"marketingDeclaredOn": "2021-03-31",
"targetSpeciesStatus": "not-reported",
"additionalMonitoring": true,
"administrativeStatus": "authorised",
"prescriptionCategory": "prescription-or-restricted",
"activeIngredientNames": [
"PÉMIGATINIB"
],
"authorisationProcedure": "Procédure centralisée",
"prescriptionConditions": [
"médicament nécessitant une surveillance particulière pendant le traitement",
"prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE",
"prescription hospitalière",
"liste I",
"prescription réservée aux médecins compétents en CANCEROLOGIE"
],
"reimbursementIndications": null,
"authorisationSourceStatus": "Autorisation active",
"europeanAuthorisationNumber": "EU/1/21/1535",
"presentationAdministrativeStatus": "authorised"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=fr" \
--data-urlencode "sourceId=fr.ansm.bdpm" \
--data-urlencode "id=fr:ansm:packages:3400930223703"